Literature DB >> 14972521

Epstein-Barr virus (EBV) LMP2A alters normal transcriptional regulation following B-cell receptor activation.

Toni Portis1, Richard Longnecker.   

Abstract

The latent membrane protein 2A (LMP2A) of Epstein-Barr virus (EBV) is an important mediator of viral latency in infected B-lymphocytes. LMP2A inhibits B-cell receptor (BCR) signaling in vitro and allows for the survival of BCR-negative B cells in vivo. In this study, we compared gene transcription in BCR-activated B cells from non-transgenic and LMP2A Tg6 transgenic mice. We found that the transcriptional induction and down-regulation of many genes that normally occurs in B cells following BCR activation did not occur in B cells from LMP2A Tg6 transgenic mice. Furthermore, LMP2A induced the expression of various transcription factors and genes associated with DNA/RNA metabolism, which may allow for the altered transcriptional regulation observed in BCR-activated B cells from LMP2A Tg6 mice. These results suggest that LMP2A may inhibit the downstream effects of BCR signaling by directly or indirectly altering gene transcription to ensure EBV persistence in infected B cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972521     DOI: 10.1016/j.virol.2003.09.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A.

Authors:  Yingchun Yan; Qing-Jie Xue; Ang Liu; Hui Wang; Honghua Zhang; Shuang Wang; Longyu Zhao; Yunqing Li; Xiuzhen Li; Yuanyuan Yang; Ting Chen; Shigen Li
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

2.  A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.

Authors:  Kathryn T Bieging; Kamonwan Fish; Subbarao Bondada; Richard Longnecker
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity.

Authors:  Mark Rovedo; Richard Longnecker
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

4.  Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen.

Authors:  Michelle A Swanson-Mungerson; Robert G Caldwell; Rebecca Bultema; Richard Longnecker
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

6.  The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling.

Authors:  Masato Ikeda; Richard Longnecker
Journal:  Virology       Date:  2008-12-10       Impact factor: 3.616

7.  Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn.

Authors:  Mark Rovedo; Richard Longnecker
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

8.  Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A.

Authors:  Takeharu Minamitani; Teruhito Yasui; Yijie Ma; Hufeng Zhou; Daisuke Okuzaki; Chiau-Yuang Tsai; Shuhei Sakakibara; Benjamin E Gewurz; Elliott Kieff; Hitoshi Kikutani
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

9.  Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection.

Authors:  Markus P Rechsteiner; Christoph Berger; Ludwig Zauner; Jürg A Sigrist; Matthias Weber; Richard Longnecker; Michele Bernasconi; David Nadal
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

10.  Epstein-Barr virus LMP2A imposes sensitivity to apoptosis.

Authors:  Michelle Swanson-Mungerson; Rebecca Bultema; Richard Longnecker
Journal:  J Gen Virol       Date:  2010-05-19       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.